Comparative Pharmacology
Head-to-head clinical analysis: TIMENTIN versus TRIMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMENTIN versus TRIMPEX.
TIMENTIN vs TRIMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Timentin is a combination of ticarcillin, a penicillin-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and clavulanic acid, a beta-lactamase inhibitor that irreversibly inhibits a wide range of beta-lactamase enzymes, thereby preventing degradation of ticarcillin and extending its spectrum to include beta-lactamase-producing organisms.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours; for moderate infections, 3.1 g IV every 6 hours; for severe infections, 3.1 g IV every 4 hours.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
None Documented
None Documented
Ticarcillin: ~1.1 hours; clavulanate: ~1.0 hours. Prolonged in renal impairment (CrCl <10 mL/min: ticarcillin half-life ~13 hours).
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Renal: 60-80% ticarcillin and 50-70% clavulanate excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal: minimal.
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Category C
Category C
Antibiotic
Antibiotic